Interestingly, a decreased level of PURPL mediated by ASOs enhances the response to the chemotherapeutic agent doxorubicin (DOX) in cultured liver cancer cells, suggesting that PURPL may have therapeutic potential in the treatment of chemoresistant HCC. The gene discussed is PURPL; the disease is liver cancer.